News & Updates

Show Multimedia Only

Small wins for amlitelimab in STREAM-AD

23 Oct 2023 by

The experimental drug amlitelimab has scored positive outcomes in the double-blind, placebo-controlled phase IIb STREAM-AD study evaluating it as a treatment for moderate-to-severe atopic dermatitis (AD).

23 Oct 2023

Nonsteroidal cream brings early relief in atopic dermatitis itch

21 Oct 2023 by

In children and adults with moderate-to-severe atopic dermatitis, applying tapinarof cream 1% helps reduce itch within 24 hours, according to the results of the phase III trials ADORING 1 and 2.

21 Oct 2023

Roflumilast serves up weight-loss benefit for patients with psoriasis

20 Oct 2023 by

In the treatment of patients with psoriasis, the phosphodiesterase (PDE)-4 inhibitor roflumilast has been found to also induce weight loss.

20 Oct 2023

Ustekinumab biosimilar shows clinical similarity to reference drug for plaque psoriasis

19 Oct 2023 by

A phase III study presented at EADV 2023 demonstrated the similarity between SB17, a human monoclonal antibody and proposed ustekinumab biosimilar, and reference ustekinumab for the treatment of moderate-to-severe plaque psoriasis.

19 Oct 2023

Original New Drug Application Approvals by US FDA (01-15 October 2023)

18 Oct 2023

New drug applications approved by US FDA as of 01-15 October 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

18 Oct 2023

ARCADIA trials: A win for nemolizumab in atopic dermatitis

17 Oct 2023 by

In the phase III ARCADIA 1 and 2 trials, the investigational, first-in-class interleukin-31-Rα antagonist nemolizumab delivered early, rapid, and sustained improvements in the core signs and symptoms of atopic dermatitis (AD) in patients with moderate-to-severe disease.

17 Oct 2023

Original New Drug Application Approvals by US FDA (15-30 September 2023)

10 Oct 2023

New drug applications approved by US FDA as of 15-30 September 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

10 Oct 2023

ALA-PDT on par with minocycline for moderate-to-severe rosacea

08 Oct 2023

Patients with moderate-to-severe rosacea may benefit from treatment with 5-aminolevulinic acid photodynamic therapy (ALA-PDT), which has shown its efficacy and noninferiority to minocycline in a recent study.

08 Oct 2023

Fostamatinib safe, effective in moderate-to-severe hidradenitis suppurativa

07 Oct 2023

Treatment with fostamatinib, a spleen tyrosine kinase inhibitor that targets B cells and plasma cells, is well tolerated by patients with hidradenitis suppurativa (HS), resulting in improved clinical outcomes with no serious adverse events, a study has shown.

07 Oct 2023

Too much animal-based protein poses increased AD risk

28 Sep 2023 by

Frequent intake of high-protein foods in diets, especially those derived from animals, appears to be associated with an increased risk of atopic dermatitis (AD) and allergic sensitization to common house dust mites, according to a study.

28 Sep 2023